Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.
Drug: Ivermectin Oral Product
3mg Capsules, 12-15mg/ day for 3 days
Inclusion Criteria:
Participants eligible for inclusion will include non-pregnant adult (>18 years old) with
molecular confirmation of COVID-19. [Participants will be eligible in a period of no longer
than 72 hours after exposure].
Exclusion Criteria:
- Severe infection ( defined as need for invasive or non-invasive ventilator support,
ECMO or shock requiring vasopressor support).
- Weight below 40Kg or above 100Kg
- Unable to take oral medication
- Known allergy to the drugs
- Pregnancy or breast feeding
- Participating in another RCT for treatment of COVID-19.
Sheba Medical Center
Ramat-Gan, Israel
Investigator: Eli Schwartz, M.D
Contact: +972-35308456
Eli.schwartz@sheba.health.gov.il
Eli Schwartz, Prof.
972 3 5308456
Eli.schwartz@sheba.health.gov.il
Asaf Biber, Dr.
972 50 7339184
Asaf.Biber@sheba.health.gov.il